Management of the adverse effects of lenalidomide in multiple myeloma. - Wikidata - awgldk - TriplyDB

Management of the adverse effects of lenalidomide in multiple myeloma.

Management of the adverse effects of lenalidomide in multiple myeloma.

http://www.wikidata.org/entity/Q33394632

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials Lenalidomide and thalidomide in the treatment of chronic pain.Anticancer Drug-Induced Acute Kidney Injury.

P2860

Q21133524-45D97ECE-FB14-41D5-BE92-0DEFBED669FA Q38084729-FE73D51A-0F64-423F-8C18-C4DD81F49C60 Q47261056-7613E60B-5083-4F54-9170-E1D1C446757A

P2860

Management of the adverse effects of lenalidomide in multiple myeloma.

http://www.wikidata.org/entity/Q33394632

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Management of the adverse effects of lenalidomide in multiple myeloma.

@ast

Management of the adverse effects of lenalidomide in multiple myeloma.

@en

type

label

Management of the adverse effects of lenalidomide in multiple myeloma.

@ast

Management of the adverse effects of lenalidomide in multiple myeloma.

@en

prefLabel

Management of the adverse effects of lenalidomide in multiple myeloma.

@ast

Management of the adverse effects of lenalidomide in multiple myeloma.

@en

P1433

Q33394632-1192745A-7796-4F0D-9360-0ED111732B3C

P1476

Q33394632-3955F96D-C937-4358-AF30-45E5066BA401

P2860

Q33394632-06AC5B9F-64FC-43AA-81DE-D0ADB662E585

Q33394632-0A45554B-32CF-46BA-ACB5-7AF979CE78E0

Q33394632-15364F1F-A926-4854-B777-DF6929C5C2E8

Q33394632-171AFA49-92D4-419A-A74E-CD6BB2A4EFC7

Q33394632-180DF032-7D83-4CC8-A265-AE3977E05F69

Q33394632-20F7A41D-EC7C-4D23-A94A-E37E1CB6B28A

Q33394632-288CAD83-9E34-4BB2-BC2C-B385F99FB01D

Q33394632-371B501E-5DA3-46CD-905D-C942CFF0F4B9

Q33394632-40D04B4F-2BCB-43E6-B912-32F8F712080D

Q33394632-47CFA01F-435C-453B-B0D7-B5E3CD100D7B

P2888

Q33394632-1CC5B84A-8EBF-4446-A382-91D77EE67312

P304

Q33394632-B3638976-41F5-4142-9A79-B7EE9B436329

P31

Q33394632-199C0053-74D3-4382-BAB9-135060B39F92

P356

Q33394632-27762543-8A77-42F6-8AAB-0B024DB0E298

P407

Q33394632-07A7C788-D3D9-4143-86F4-B2B3E686B14F

P478

Q33394632-C16225DD-872D-4E9E-A053-820820617DCF

P50

Q33394632-74C29B81-A8CF-4252-BB47-B676BC50F709

P577

Q33394632-288C3E5F-A7DE-4F83-ABBD-09206A5FE311

P5875

Q33394632-6C4D91CF-A4BF-4338-A763-7C3542A82736

P6179

Q33394632-D9C95C40-88AF-4A3A-ACDE-355CC492ABA4

P698

Q33394632-77D8FF78-AA28-4DBB-AEC7-946F7396814E

P356

S12325-010-0104-8

P1433

Advances in Therapy

P1476

Management of the adverse effects of lenalidomide in multiple myeloma.

@en

P2860

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

P2888

s12325-010-0104-8

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-010-0104-8

http://www.w3.org/2001/XMLSchema#string

P407

P478

28 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Ana Pilar González Rodríguez

P577

2011-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50934620

http://www.w3.org/2001/XMLSchema#string

P6179

1020069809

http://www.w3.org/2001/XMLSchema#string

P698

21431626

http://www.w3.org/2001/XMLSchema#string